Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
YATHARTHBSEYATHARTH HOSP & TRA C S L· Healthcare ServicesHighPositive
Announced Mon, 10 Aug, 2026 · 16:29 IST

Yatharth Q1FY27: revenue up 35% YoY, Rs 0.50 interim dividend

Revenue Growth 20pctResults View source PDFExplain this filing

YATHARTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.9%Reaction day
₹900.00
prior close
₹910.50
announcement price
After-mkt
timing
Nifty Microcap 250market-0.2%-3.7% vs market
Hospital peers, median of 25sector-1.2%-2.7% vs sector

On the reaction day the stock moved 3.7 pts less than Nifty Microcap 250 and 2.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.1
10m
+0.7
15m
+0.2
30m
-2.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.9-0.2-3.7-1.2-2.7
Next day
-3.9+0.2-4.1-2.1-1.7
2d
-6.3+0.4-6.7-2.9-3.5
3d
-5.6+0.4-6.0-1.7-3.9
4d
-6.4+0.6-7.0-2.5-3.9
5d
-4.8+0.9-5.7-2.1-2.7
1w
-5.6+0.9-6.4-3.4-2.2
15d
+8.5+0.9+7.5-4.2+12.6
1m
+7.7+2.3+5.3-3.0+10.7
2m
+10.3-1.1+11.4-12.8+23.1
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Yatharth's Q1FY27 standalone revenue rose 34.9% YoY to Rs 1,763.08 million; PAT at Rs 281.68 million versus Rs 271.22 million last year. Consolidated revenue jumped 51.5% to Rs 3,926.54 million, PAT Rs 454.23 million. Board declared first interim dividend of Rs 0.50 per share (5%), record date August 14, 2026. New ESOP 2026 covering 2.5 lakh shares was approved. Statutory auditor changed; MSKA reviewed Q1FY27 while a different firm reviewed Q1FY26.

Likely market impact

Strong topline growth on standalone and consolidated basis, stable profits, small interim dividend, and noted change of statutory auditor for transparency.